These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11489662)

  • 1. Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
    Avalos M; Mak C; Randall PK; Trzeciakowski JP; Abell C; Kwan SW; Wilcox RE
    J Pharmacol Toxicol Methods; 2001; 45(1):17-37. PubMed ID: 11489662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved models for pharmacological null experiments: calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines.
    Mak CK; Avalos M; Randall PK; Kwan SW; Abell CW; Neumeyer JL; Whisennand R; Wilcox RE
    Neuropharmacology; 1996 May; 35(5):549-70. PubMed ID: 8887963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D1 dopamine receptor activity of anti-parkinsonian drugs.
    Fici GJ; Wu H; VonVoigtlander PF; Sethy VH
    Life Sci; 1997; 60(18):1597-603. PubMed ID: 9126882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors.
    Zackheim JA; Abercrombie ED
    Brain Res Bull; 2001 Apr; 54(6):603-7. PubMed ID: 11403986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors?
    Jackson DM; Wikström H; Liao Y
    Psychopharmacology (Berl); 1998 Jul; 138(2):213-6. PubMed ID: 9718292
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
    Ralph RJ; Caine SB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
    Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
    J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S; Bergman J
    Eur J Pharmacol; 1994 Aug; 260(2-3):237-41. PubMed ID: 7988649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
    Jutkiewicz EM; Bergman J
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors.
    Cheung TH; Bezzina G; Hampson CL; Body S; Fone KC; Bradshaw CM; Szabadi E
    Psychopharmacology (Berl); 2007 Dec; 195(2):213-22. PubMed ID: 17668188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia.
    O'Neill MJ; Hicks CA; Ward MA; Cardwell GP; Reymann JM; Allain H; Bentué-Ferrer D
    Eur J Pharmacol; 1998 Jul; 352(1):37-46. PubMed ID: 9718265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat.
    Wachtel SR; Brooderson RJ; White FJ
    Psychopharmacology (Berl); 1992; 109(1-2):41-8. PubMed ID: 1365670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopamine D-1 and D-2 receptors on intraocular pressure in conscious rabbits.
    Prünte C; Nuttli I; Markstein R; Kohler C
    J Neural Transm (Vienna); 1997; 104(2-3):111-23. PubMed ID: 9203075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
    J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
    Tidey JW; Bergman J
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
    Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
    Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
    Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
    Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
    Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.